Robert H Vonderheide MD

Oncology•Philadelphia, PA

Physician

Join to View Full Profile

3400 Civic Center Boulevard12-114 SouthPhiladelphia, PA 19104
Phone+1 215-662-3929
Fax+1 215-573-2652

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1996 - 1998
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 1993 - 1996
Harvard Medical SchoolClass of 1993

Certifications & Licensure

PA State Medical License 2001 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Elected Member The American Society for Clinical Investigation, 2007

Clinical Trials

Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma Start of enrollment: 2010 Feb 01
Completed
Phase 1
Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma Start of enrollment: 2012 Apr 01
Completed
Phase 1
Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors Start of enrollment: 2005 Jul 01
Completed
Early Phase 1
Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors Start of enrollment: 2004 Jan 01
Completed
Phase 1
hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Start of enrollment: 2014 Dec 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of PDAC.
Margo I Orlen, William P Vostrejs, Rina Sor, Jayne C McDevitt, Samantha B Kemp
Cancer Discovery. 2025-03-07
2 citations
Pivotal roles for cancer cell-intrinsic mPGES-1 and autocrine EP4 signaling in suppressing antitumor immunity.
Nune Markosyan, Il-Kyu Kim, Charu Arora, Liz Quinones-Ware, Nikhil Joshi
JCI Insight. 2024-11-08
Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer.
Urszula N Wasko, Jingjing Jiang, Tanner C Dalton, Alvaro Curiel-Garcia, A Cole Edwards
Nature. 2024-11-01

Journal Articles

Unique Pattern of Neutrophil Migration and Function During Tumor Progression
Neil Hockstein, Charles Mulligan, Robert H Vonderheide, Gregory Masters, Nature
Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer
Andrew J Rech, Robert H Vonderheide, Jonathan J Kotzin, Clinical Cancer Research

Press Mentions

HMN 2025: How Immunotherapy Could Increase KRAS-Targeted Remedy in Pancreatic CancerMarch 15th, 2025
Immunotherapy May Boost KRAS-Targeted Therapy in Pancreatic CancerMarch 14th, 2025
Immunotherapy Enhances Effectiveness of KRAS-Targeted Treatments in Pancreatic CancerMarch 14th, 2025
Join now to see all

Grant Support

Abramson Cancer Center Support GrantUNIVERSITY OF PENNSYLVANIA1997–2025
Combined CD40 Activation And CTLA4 Blockade In MelanomaNational Cancer Institute2011–2012
Immunoregulation And Immunotherapy Of Breast CancerNational Cancer Institute2005–2011
Telomerase As A Widely Expressed Tumor AntigenNational Cancer Institute2001–2004
Telomerase As A Widely Expressed Tumor AntigenNational Cancer Institute2000–2001